Assays and screens

TECHNOLOGY: Bioinformatic screens; cell-free assays

A low-cost computational method for quantifying tumor cfDNA could identify cancer patients eligible for high-cost, whole-exome sequencing-based personalized medicine. The method

Read the full 252 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE